Please assess the completion status of the following clinical trial:

Trial Title: Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between the ages of 18 and 75 years admitted to a general medicine or surgical services.~* A known history of type 2 diabetes mellitus \> 3 months, receiving either diet alone, oral monotherapy, or with any combination of oral antidiabetic agents (sulfonylureas, meglitinides, metformin, thiazolidinediones, dipeptidyl peptidase (DPP) IV inhibitors).~* Patients admitted for non-cardiac elective or emergency surgery or trauma.~* Subjects must have an admission BG \> 140 mg and \< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (bicarbonate \< 18 milliequivalent /L, potential hydrogen (pH) \< 7.30, or positive serum or urinary ketones).~Exclusion Criteria:~* Subjects with increased blood glucose concentration, but without a known history of diabetes (stress hyperglycemia).~* Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria \[32\].~* Patients with acute critical or surgical illness admitted to the ICU or expected to require admission to the ICU.~* Patients admitted for coronary artery bypass graft (CABG) or patients receiving continuous insulin infusion.~* Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, or impaired renal function (creatinine ≥ 3.0 mg/dl).~* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~* Female subjects are pregnant or breast feeding at time of enrollment into the study.~* Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.~* Female subjects are pregnant or breast feeding at time of enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Basal Plus Regimen (Type: EXPERIMENTAL): glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
- Basal Bolus (Type: EXPERIMENTAL): glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
- sliding scale regular insulin (SSRI) (Type: ACTIVE_COMPARATOR): sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.

Based on this trial design, predict the completion outcome and termination type (if applicable).